🔎 Trials Near Me

Home › Colite ulcerosa › Ohio

Studi clinici su Colite ulcerosa nello stato di Ohio

26 studi su Colite ulcerosa cercano partecipanti presso sedi nello stato di Ohio.

Città nello stato di Ohio

Testo ufficiale dello studio (inglese)

Study of Advanced Therapies for the Treatment of Adult Participants With Moderately to Severely Active Crohn's Disease or Ulcerative Colitis

  • Gastro Intestinal Research Institute of Northern Ohio /ID# 283860, Westlake
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 1 ott 2026 · NCT07697456

A Study of Vedolizumab in Adults With Ulcerative Colitis (UC) or Crohn's Disease (CD) in the Community Setting

  • Gastro Health Research - Cincinnati, Cincinnati
  • DSI Research Northridge LLC, Dayton
  • Gastro Health Research - Liberty Township, Liberty Township
  • e altri 3
In reclutamentoFase 4
Età da 18 a 80 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06581328

A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis

  • University Hospitals Cleveland Medical Center /ID# 271831, Cleveland
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT07071519

A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis

  • GCGA Physicians, LLC dba / Gastro Health Research, Cincinnati
  • NexGen Research, Lima
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 30 set 2026 · NCT06598943

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

  • Xencor Investigative Site, Beavercreek
In reclutamentoFase 1/2Volontari sani benvenuti
Età da 18 a 75 · Tutti i sessi · Aggiornato il 29 set 2026 · NCT06619990

A Trial to Investigate PALI-2108 Versus Placebo in Participants With Moderately to Severely Active Ulcerative Colitis

  • Site US-025, Brunswick
  • Site US-023, Dayton
  • Site US-027, Westlake
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 29 set 2026 · NCT07845487

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants

  • Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamentoFase 3
Età 3 e oltre · Tutti i sessi · Aggiornato il 25 set 2026 · NCT06663332

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

  • Cleveland Clinic, Cleveland
In reclutamentoFase 2/3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT05076175

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

  • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
In reclutamentoFase 3
Età da 18 a 70 · Tutti i sessi · Aggiornato il 24 set 2026 · NCT06937086

Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

  • Ohio State University Comprehensive Cancer Center, Columbus
In reclutamentoFase 1
Età 18 e oltre · Tutti i sessi · Aggiornato il 23 set 2026 · NCT03816345

LY4268989 (MORF-057) Co-Administered With Mirikizumab in Adults With Moderately to Severely Active Ulcerative Colitis:

  • Dayton Gastroenterology, LLC, Dayton
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07186101

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

  • Ohio State University, Hilliard
  • DSI Research, LLC d/b/a ObjectiveHealth Clinical Research - Springboro, Springboro
  • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 22 set 2026 · NCT07415044

A Study of Vedolizumab With Tofacitinib in Adults With Ulcerative Colitis (UC)

  • University of Cincinnati, Cincinnati
  • Ohio Gastroenterology group, Inc., Columbus
  • Gastro Intestinal Research Institute of Northern Ohio, LLC., Westlake
In reclutamentoFase 4
Età da 18 a 65 · Tutti i sessi · Aggiornato il 21 set 2026 · NCT06095128

Proof of Concept Study Evaluating the Efficacy and Safety of ATH-063 Treatment in Patients With Relapsed/Refractory Moderately to Severely Active Ulcerative Colitis (UC)

  • Cleveland Clinic Foundation, Cleveland
In reclutamentoFase 2
Età da 18 a 75 · Tutti i sessi · Aggiornato il 21 set 2026 · NCT07513181

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  • Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
  • OSU Wexner Medical Center - Site Number: 8400077, Columbus
  • North Shore Gastroenterology Research - Site Number: 8400130, Westlake
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 15 set 2026 · NCT07185009

A Study of JNJ-78934804 in Participants With Moderately to Severely Active Ulcerative Colitis

  • Great Lakes Gastroenterology Research, LLC, Mentor
In reclutamentoFase 3
Età 18 e oltre · Tutti i sessi · Aggiornato il 28 ago 2026 · NCT07577856

An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis

  • Gastroenterology & Hepatology Specialists, Inc. - Site Number: 8400139, Canton
  • Ohio Gastroenterology Group Inc. - Site Number: 8400006, Columbus
  • OSU Wexner Medical Center - Site Number: 8400077, Columbus
  • e altri 4
In reclutamentoFase 3
Età da 16 a 80 · Tutti i sessi · Aggiornato il 20 ago 2026 · NCT07184996

Zymfentra (Infliximab-dyyb) REal World Cohort STudy

  • University of Cincinnati, Cincinnati
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 5 ago 2026 · NCT07237516

An Observational Study of Etrasimod in Adult Patients With Moderate to Severe Ulcerative Colitis

  • University of Cincinnati College of Medicine, Cincinnati
  • Gastro Intestinal Research Institute of Northern Ohio, LLC, Westlake
In reclutamentoStudio osservazionale
Età da 18 a 64 · Tutti i sessi · Aggiornato il 9 lug 2026 · NCT06398626

A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis

  • University Hospitals Cleveland Medical Center Rainbow Babies & Children's Hospital, Cleveland
  • University Hospitals Cleveland Medical Center, Cleveland
In reclutamentoFase 2
Età da 12 a 17 · Tutti i sessi · Aggiornato il 8 lug 2026 · NCT05287126

A Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Children's Clinic, Cleveland
  • Cleveland Clinic, Cleveland
In reclutamentoFase 3
Età da 2 a 17 · Tutti i sessi · Aggiornato il 22 giu 2026 · NCT06405087

A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)

  • University Hospitals Cleveland Medical Center - 11100 Euclid Ave, Cleveland
In reclutamentoFase 3
Età 2 e oltre · Tutti i sessi · Aggiornato il 7 mag 2026 · NCT05442567

ALPCO Calprotectin CLIA Assay - Measurement of Calprotectin Levels in Human Stool

  • Gastro Intestinal Research Institute of Northern Ohio,, Westlake
In reclutamentoStudio osservazionaleVolontari sani benvenuti
Età 22 e oltre · Tutti i sessi · Aggiornato il 28 apr 2026 · NCT06810518

A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease

  • Mirador Therapeutics Selected Site, Cincinnati
  • Mirador Therapeutics Selected Site, Liberty Township
In reclutamentoFase 2
Età da 18 a 80 · Tutti i sessi · Aggiornato il 12 mar 2026 · NCT07113522

Evaluation of the SMART IBD App in Pediatric IBD

  • Cincinnati Children's Hospital Medical Center, Cincinnati
In reclutamento
Età da 13 a 17 · Tutti i sessi · Aggiornato il 21 nov 2025 · NCT07195123

Study of Efficacy and Adherence to Subcutaneous vs. Intravenous Vedolizumab in Patients With Inflammatory Bowel Disease Using a Novel Remote MONITORing Intervention

  • University of Cincinnati, Cincinnati
In reclutamentoStudio osservazionale
Età 18 e oltre · Tutti i sessi · Aggiornato il 8 mag 2025 · NCT06750731

Fonte: ClinicalTrials.gov, dati recuperati il 2 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.